Trelstar® Prescription Fulfillment Program
- No out-of-pocket costs
- No inventory to manage
- No need to complete prior authorizations
- No drug claims to submit
Follow these simple steps to prescribe Trelstar via CareMed™:
1. Download, complete, and fax the simple prescription form. Prescription Form (PDF)
- You will receive a confirmation call when CareMed™ receives the fax
- Electronic prescribing is also available! E-prescribing Overview (PDF)
2. Inform the patient that CareMed™ will be handling their specialty prescription.
- CareMed™ will investigate copay assistance on behalf of the patient and bill the patient for their copay Patient Hand Out (PDF)
3. Trelstar is delivered based on your preference:
- To your office or patient's home on the date you request
- 24 hour turnaround and overnight delivery available
- Refill reminders, refill verification, or auto-refill offered
For more information, reference the forms below or call CareMed™ at (877) 227-3405
Program Overview (PDF)
Frequently Asked Questions (PDF)
Watson Pharma, Inc. and CareMed™ Pharmaceutical Services are parties to the CareMed™ Prescription Fulfillment Program (PFP). CareMed™ is a specialty pharmacy that provides Trelstar® and other services to physician offices and to patients.
Indication
Trelstar® is indicated for the palliative treatment of advanced prostate cancer.
Important Safety Information
The most commonly reported adverse events associated with the use of Trelstar® 22.5 mg included hot flushes (71.7%), erectile dysfunction (10.0%), and testicular atrophy (7.5%) • The most commonly reported adverse events associated with the use of Trelstar® 3.75 mg/Trelstar® 11.25 mg included hot flushes (58.6%/73.0%), skeletal pain (12.1%/13.2%), impotence (7.1%/2.3%), headache (5.0%/6.9%), leg pain (2.1%/5.2%), and edema in legs (0.0%/6.3%) • Trelstar® is contraindicated in women who are or may become pregnant as well as patients who are hypersensitive to triptorelin, other GnRH agonists, or GnRH • Anaphylactic shock, hypersensitivity, and angioedema related to triptorelin administration have been reported • Trelstar® causes an initial transient increase in testosterone levels. Patients may experience the onset or exacerbation of symptoms during this period, including bone pain, neuropathy, hematuria, urethral or bladder outlet obstruction, or spinal cord compression that may contribute to weakness or paralysis with or without fatal complications. Patients with metastatic vertebral lesions and/or urinary tract obstruction should be closely observed. Hyperglycemia and an increased risk of developing diabetes, as well as increased risk of myocardial infarction, sudden cardiac death, and stroke have been reported in men receiving GnRH analogs. Patients should be monitored for blood glucose level and cardiovascular disease, and managed according to current clinical practice
MIXJECT® is a registered trademark of Medimop Medical Projects Ltd.
